



Ref. No.: EIKO/BSE/2023-24/49

**Date:** 25<sup>th</sup> January, 2024

To,  
Corporate Services Department,  
**BSE Limited,**  
P J Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

**Scrip Code:** 540204

**Sub: Outcome of the Board Meeting and Disclosure Regulation 30 of SEBI ((Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir/Madam,

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations'), we would like to inform you that the Board of Directors in their meeting held today has considered and approved the below transaction:

- Company ('ELL') to enter into definitive business agreement with Vivacious Pharmatex Private Limited (VPPL) for Company's Growth and strategic positioning.

Details as required under listing regulations and SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are marked as **Annexure-A**

The Meeting started at 10:00 AM and concluded at 11:00 AM

Please take the same on your record and oblige.

Thanking you,

For **EIKO LIFESCIENCES LIMITED**

---

**Jaid Kojar**  
**Chief Financial Officer**

**Annexure A****Disclosure under Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI LODR) and SEBI Circular bearing reference SEBI/ HO/ CFD/ CFD-PoD-1/ P/ CIR/ 2023/ 123 dated July 13, 2023.**

<b>Name of the entity(ies) with whom agreement is signed</b>	Vivacious Pharmatex Private Limited (VPPL)
<b>Area of agreement</b>	Dynamic Collaboration & Strategic Partnership
<b>Domestic/international</b>	Domestic
<b>Share exchange ratio</b>	Not Applicable
<b>Scope of business operation of agreement</b>	Company and VPPL will support each other in development and marketing of products.
<b>Details of consideration paid / received in agreement</b>	Not Applicable
<b>Significant terms and conditions of agreement in brief</b>	Strategic expansion for Eiko Lifesciences Limited into the "Oleochemicals and Allied Business" segment, a domain integral to products in personal care, pharmaceuticals, agrochemicals, paints, coatings, fragrance, polymer, and petrochemicals.
<b>Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"</b>	No
<b>Size of the entity(ies)</b>	Not Applicable
<b>Rationale and benefit expected</b>	<p>By Entering into this agreement, Company will be preferred business partner for VPPL in terms of sourcing and supplying key raw materials.</p> <p>Further VPPL, will provide full co-operation in developing new products, commercialization, and marketing at our manufacturing facilities.</p> <p>Further, Company stands to gain from the vast knowledge, expertise, and research and development skills of the new management at VPPL. This collaboration is poised to be synergistic, ensuring innovation, growth, and success for both ELL and VPPL.</p>